Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2019

The Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019: Deal trends, players, financials and forecasts report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.



This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:


Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.



This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.



The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.



Chapter 3 provides a review of the leading monoclonal antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.



Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.



Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.



Chapter 7 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2014. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.



In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.



The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.



Key benefits




Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019 provides the reader with the following key benefits:



In-depth understanding of monoclonal antibodies deal trends since 2014
Access to headline, upfront, milestone and royalty data
Access to the structure of monoclonal antibodies agreements with numerous real life case studies
Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world’s biopharma companies
Identify the leading monoclonal antibody partnering companies
Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope



Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019 is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.



Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2019 includes:



o Trends in monoclonal antibodies dealmaking in the biopharma industry since 2014

o Analysis of monoclonal antibodies deal structure

o Access to headline, upfront, milestone and royalty data

o Access to over 640 monoclonal antibodies deal records

o The leading monoclonal antibodies deals by value since 2014

o Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2014



In Global Monoclonal antibody Partnering Terms and Agreements 2014 to 2098, the available deals are listed by:



o Company A-Z

o Headline value

o Stage of development at signing

o Deal component type

o Monoclonal antibodies type



Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.



The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2019 report provides comprehensive access to available deals and contract documents for over 700 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:



What are the precise monoclonal antibody rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

 

Executive Summary



Chapter 1 – Introduction



Chapter 2 – Trends in monoclonal antibody dealmaking



2.1. Introduction
2.2. Monoclonal antibody partnering over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody partnering by deal type
2.5. Monoclonal antibody partnering by therapy area
2.6. Deal terms for monoclonal antibody partnering
2.6.1 Monoclonal antibody partnering headline values
2.6.2 Monoclonal antibody deal upfront payments
2.6.3 Monoclonal antibody deal milestone payments
2.6.4 Monoclonal antibody royalty rates



Chapter 3 – Leading monoclonal antibody deals



3.1. Introduction
3.2. Top monoclonal antibody deals by value



Chapter 4 – Most active monoclonal antibody dealmakers



4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody partnering company profiles



Chapter 5 – Monoclonal antibody contracts dealmaking directory



5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory



Chapter 6 – Monoclonal antibody dealmaking by technology type



Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb



Chapter 7 – Partnering resource center



7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking



Appendices



Appendix 1 – Monoclonal antibody deals by company A-Z



Appendix 2 – Monoclonal antibody deals by stage of development



Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation



Appendix 3 – Monoclonal antibody deals by deal type



Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination



Appendix 4 – Monoclonal antibody deals by therapy area



Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Hematology
Hospital care
Immunology
Infectives
Metabolic
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory



Appendix 5 –Deal type definitions


About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering


Table of figures



Figure 1: Therapeutic antibody definitions
Figure 2: Monoclonal antibody partnering since 2014
Figure 3: Active monoclonal antibody dealmaking activity since 2014
Figure 4: Monoclonal antibody partnering by deal type since 2014
Figure 5: Monoclonal antibody partnering by disease type since 2014
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2014
Figure 11: Most active monoclonal antibody dealmakers since 2014
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events

 


2020 Global Virology and Bacteriology Market for over 100 Tests: US, Europe, Japan--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Emerging Technologies, Instrumentation, Opportunities

This new report is a seven-country strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key trends in the U.S.,

USD 28500 View Report

2020 Global Transfusion Medicine Market for Over 40 Immunohematology and NAT Tests: Supplier Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers

This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global transfusion diagnostic market during the next five years,

USD 18500 View Report

COVID-19 Outbreak-Global Monoclonal Antibody Based Products Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

The Monoclonal Antibody Based Products market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.Under COVID-19 outbreak

USD 3660 View Report

Global Monoclonal Antibodies Market Research Report 2019-2023

Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. In the context of China-US trade war and global economic

USD 2850 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available